ByteDance’s Anew Labs Spin-Off: What the $290M Deal Means

ByteDance has reportedly completed the first outside funding round for Anew Labs, the AI drug-discovery business it spun out of the group. The reported $290 million financing values the Shanghai-headquartered company at $1.5 billion, while ByteDance retains a 56% stake after the round. The details come from people familiar with the transaction, rather than a public announcement from ByteDance or Anew. 14

The deal at a glance

The transaction is best understood as a controlled carve-out. Anew can raise capital and operate as a distinct life-sciences business, but ByteDance remains its majority shareholder.

• Capital raised: $290 million in Anew’s inaugural external round. 1
• Reported valuation: $1.5 billion following the financing. 1
• ByteDance ownership: 56% after the round, according to reporting citing a source familiar with the matter. 4
• Headquarters: Shanghai. 1
• Lead investors: HSG, formerly Sequoia China; IDG Capital; and Hillhouse Investment. 5Y Capital was reported as a co-lead. 1
• Other reported investors: Gaorong Ventures, Primavera Venture Partners, Boyu Capital, Sino Biopharmaceutical, and the state-backed Shanghai Future Industries Fund. 4

What is moving into Anew Labs

Initial reporting on the separation said ByteDance would transfer the core AI-for-pharma team, core algorithms, technology platform and existing pipeline assets into the new entity. The core team was reported to comprise about 50 people. 132

ByteDance is also expected to remain an important infrastructure partner. The unit was reported to continue receiving computing-power support from Volcano Engine, ByteDance’s cloud and AI-infrastructure business. 13

That combination matters: Anew receives a more independent corporate structure and external funding, but it is not starting from scratch. It inherits personnel, research assets and an ongoing compute relationship from its former parent.

Why a separate company?

The spin-off is a route to commercialize ByteDance’s AI-for-science work as a dedicated drug-discovery business. Reporting on the transaction frames it as independent financing for an operation that ByteDance will still control. 1315

In practical terms, drug discovery requires a different operating model from a consumer-internet platform: long research timelines, specialized scientific hiring, pipeline development and capital that can support a biotech-style business. A separate entity gives Anew a clearer vehicle to pursue those needs while ByteDance preserves a majority stake and infrastructure connection. This is an interpretation of the reported structure, not a disclosed detailed rationale from ByteDance.

Leadership and international footprint

Anew’s work grew out of ByteDance’s AI-for-Science effort, which reporting says was established in 2021 and led by Liu Kai. 2

Anew’s website lists offices in Shanghai, San Francisco and Singapore, indicating that the company is building a cross-border AI and drug-discovery organization rather than operating solely from its Shanghai headquarters.

The technology and early pipeline

Public reporting has associated Anew with several AI research tools, including protein-structure prediction, protein design and generative molecular design. AnewOmni, for example, has been described as a generative framework for designing functional molecules across molecular scales. 9

Its most visible reported program is an AI-designed small molecule targeting IL-17, a protein involved in inflammatory and autoimmune biology. Anew presented the program at an immunology conference in Boston; coverage described it as the unit’s first public AI-designed therapy and as an effort to address a protein–protein interaction that has been difficult to target with conventional small molecules. 9

That scientific disclosure should be viewed cautiously. A conference presentation and a preclinical discovery program are not proof of human efficacy, regulatory approval or a commercial medicine. The provided reporting does not establish that the IL-17 candidate has entered clinical trials or produced clinical data. 9

What the spin-off signals

Anew Labs gives ByteDance a dedicated vehicle for converting AI-for-science research into a drug-discovery business. Outside investors bring fresh funding and biotechnology-focused backing; ByteDance contributes a majority ownership position, transferred research assets and continued compute support. 113

The $1.5 billion reported valuation shows investor interest in that model, but Anew’s long-term test will be scientific and operational: whether its platform can repeatedly produce drug candidates that advance through the demanding stages of development beyond early research.